David J Goldstein
Affiliation: Eli Lilly and Company
- Duloxetine in the treatment of major depressive disorder: a double-blind clinical trialDavid J Goldstein
Eli Lilly and Company, and Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis 46285, USA
J Clin Psychiatry 63:225-31. 2002..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression...
- Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depressionMichael J Detke
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
J Psychiatr Res 36:383-90. 2002..There was no significant incidence of hypertension, nor any other safety issues. Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD...
- Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trialMichael J Detke
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
J Clin Psychiatry 63:308-15. 2002..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for efficacy and tolerability/safety in the treatment of MDD and associated physical symptoms...
- Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety studyJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, Toronto, Canada
Pain Med 7:373-85. 2006..This study assessed the 6-month safety and tolerability of duloxetine in patients with DPNP; evaluation of efficacy was a secondary objective...
- Duloxetine in the long-term treatment of major depressive disorderJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Avenue, Scarborough, Ontario, Canada M1N 2E8
J Clin Psychiatry 64:1237-44. 2003..This clinical trial evaluated the long-term (1 year) safety and efficacy of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, in patients with DSM-IV major depressive disorder...
- Duloxetine in treatment of anxiety symptoms associated with depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, Seattle, WA, USA
Depress Anxiety 18:53-61. 2003..Efficacy in these three key symptom domains may in turn explain the high probabilities of remission (43-57%) observed in these studies...
- The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibitionStephane Chalon
Neuropsychopharmacology 26:698-9; author reply 700-1. 2002
- Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetineDavid J Goldstein
PRN Consulting, Indianapolis, IN, USA
J Clin Psychopharmacol 24:389-99. 2004..Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder...
- A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorderLesley M Arnold
University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
Arthritis Rheum 50:2974-84. 2004..To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder...
- Duloxetine vs. placebo in patients with painful diabetic neuropathyDavid J Goldstein
PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
Pain 116:109-18. 2005..Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain...
- A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorderLesley M Arnold
Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
Pain 119:5-15. 2005..In conclusion, both duloxetine 60 mg QD and duloxetine 60 mg BID were effective and safe in the treatment of fibromyalgia in female patients with or without major depressive disorder...
- Effects of duloxetine on painful physical symptoms associated with depressionDavid J Goldstein
Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
Psychosomatics 45:17-28. 2004..Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression...
- Adverse pregnancy outcomes with SSRIsDavid J Goldstein
Am J Obstet Gynecol 196:e25; author reply e25. 2007